Deals channel feed

Ex­clu­sive: Strug­gling Ed­i­tas shops pre­clin­i­cal can­cer pipeline dur­ing its big makeover

3 years ago

Up­dat­ed: Not known for gene ther­a­py plays, Eli Lil­ly ac­quires hear­ing loss start­up Ak­ou­os for $487M plus CVR

3 years ago
Cell/Gene Tx

Ko­re­an buy­er jumps in­to M&A game with $566M bid for Aveo On­col­o­gy

3 years ago

GSK ex­pands AI part­ner­ship with Tem­pus, fronting $70M for ac­cess to 'mul­ti­modal data'

3 years ago
AI

Gilead calls dibs on a PhI bis­pe­cif­ic, hands over $60M to cash-strapped Macro­Gen­ics

3 years ago

Six biotechs merge to take on Bridge­Bio, Abeona in 'but­ter­fly skin' dis­ease, with eyes al­so set on Duchenne

3 years ago
Financing
Startups

Imara puts an end to its strug­gles as Or­biMed, 5AM-backed pre­ci­sion on­col­o­gy play­er rides the shell to Nas­daq

3 years ago

Up­dat­ed: Bridge­Bio's $2.4B part­ner­ship takes a sud­den hit as Helsinn plans to with­draw NDA on FGFR2 drug

3 years ago
R&D
Pharma

Amid a glob­al build­out, Cy­ti­va ac­quires a provider of vi­ral vec­tor man­u­fac­tur­ing tech­nolo­gies

3 years ago
Pharma
Manufacturing

Vi­a­tris weighs sale of Eu­ro­pean con­sumer health busi­ness — re­port

3 years ago
Pharma

Mer­ck pays Mod­er­na $250M to con­tin­ue Keytru­da, can­cer vac­cine com­bo stud­ies

3 years ago
R&D

Roy­al­ty Phar­ma bets Mer­ck­'s schiz­o­phre­nia drug can go where Pfiz­er, Take­da and Lund­beck­'s couldn’t

3 years ago
Financing
Pharma

Months af­ter adding $60M to cof­fers, AI start­up Ter­ray nabs dis­cov­ery pact with Google's Cal­i­co

3 years ago
AI

‘Pluck those di­a­monds’: Bay­er’s Vi­vid­ion eyes up to nine on­col­o­gy tar­gets from Duke spin­out

3 years ago
Startups
Pharma

Now bank­rupt, Zosano sells off its drug de­liv­ery tech that once en­ticed No­vo Nordisk, Eli Lil­ly

3 years ago

Pfiz­er ex­ec de­nies vac­cine ne­go­ti­a­tions via text mes­sage in grilling be­fore Eu­ro­pean Par­lia­ment

3 years ago
Pharma
Coronavirus

Eli Lil­ly tasks Nim­bus with hit­ting a 'high-val­ue' tar­get for di­a­betes, obe­si­ty

3 years ago

Il­lu­mi­na con­tin­ues trek in­to drug dis­cov­ery, inks AI pact with As­traZeneca

3 years ago
AI

PureTech, Nek­tar put an end to deal dis­cus­sions, cit­ing too much 'uncer­tain­ty'

3 years ago

Gink­go inks $144M deal with Mer­ck to en­gi­neer en­zymes to im­prove in­gre­di­ent man­u­fac­tur­ing

3 years ago
Manufacturing

At­trac­tive M&A op­tions? An­a­lysts break down what's hot right now

3 years ago
Pharma

BioN­Tech al­lies with Aus­tralian state, ini­tial­iz­ing plans to con­struct new R&D and man­u­fac­tur­ing fa­cil­i­ties

3 years ago
Manufacturing

An AI, err ma­chine learn­ing, shop lines up Eli Lil­ly as part­ner ahead of first in-house clin­i­cal tri­al

3 years ago
AI
Pharma

Ris­ing from the IL-2 ash­es and dras­tic re­org, Nek­tar in merg­er talks with PureTech

3 years ago
First page Previous page 48495051525354 Next page Last page
A service from the Financial Times